

REVIEW

Open Access



Translating multi-omics into healthcare: requisites for scalable and equitable implementation

Birute Tumiene¹, David R. Adams², Robert Allaway³, Maria J. Barrero⁴, Chun-Hung Chan⁵, Víctor Faundes⁶, Vanessa S. Fear⁷, Polina Glezer⁸, Claudia Fuchs⁹, Tudor Groza^{10,12,21,22}, Elisa J. F. Houwink¹¹, Saumya Shekhar Jamuar^{10,12}, Mary Catherine V. Letinturier¹³, Richa Madan Lomash¹⁴, Ratna Dua Puri¹⁵, Juergen K. V. Reichardt¹⁶, Ruty Mehrian-Shai¹⁷, Francois H. van der Westhuizen¹⁸, Gaurav K. Varshney¹⁹, Shinya Yamamoto²⁰ and Gareth Baynam^{21*}

Abstract

Multi-omics in combination with advanced computational methodologies synthesizes diverse omics data to provide deeper insights into molecular interactions and offers transformative potential for unravelling phenomenon behind disease complexities, improving diagnostics, disease prevention, and personalized treatments. This integrative strategy enables our understanding of gene-environment relationships, chronic disease progression, and the intricate molecular pathways involved in health. Effective multi-omics analyses require robust data sharing, accessibility, interoperability, and governance, which are critical for linking genomic elements to phenotypic traits. The Global Alliance for Genomics and Health advocates for responsible data-sharing practices, by promoting key principles such as transparency and equity. By emphasizing a collaborative approach to data utilization, our proposed framework seeks to advance improved disease prevention and treatment strategies. Multi-disciplinary collaboration, encompassing researchers, clinicians, policy makers, and patient representatives, is pivotal for driving innovation and addressing rare disease diagnostics. The success of multi-omics applications hinges on the establishment of comprehensive datasets, understanding the functional implications of multi-omic variation, adherence to findable, accessible, interoperable, reusable (FAIR) and Collective Benefit, Authority to Control, Responsibility, and Ethics (CARE) principles, and the strengthening of global genomic commons, benefiting scientific research, drug development, and broader health initiatives. Our review highlights essential components of multi-omics integration, underscoring its potential to transform the landscape of precision medicine and improved patient outcomes worldwide.

Keywords Omics, Health data, Multi modal data, Rare diseases, Health equity

*Correspondence:
Gareth Baynam
gareth.baynam@health.wa.gov.au

Full list of author information is available at the end of the article



© The Author(s) 2026. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Introduction

Omics techniques provide thorough evaluations of various biological molecules, including RNA and metabolites. These methods have transformed modern medicine by enhancing our knowledge of the functional implications of molecular intricacies involved in health and disease. Recent advancements in various omics technologies, including proteomics and metabolomics, alongside improved computing capabilities, have facilitated a new approach known as multi-omics. This approach synergistically combines different types of omics data, allowing for a deeper understanding of the intricate molecular interactions involved in health and disease. The resources, methods, and technologies can be effectively utilized, and the existing challenges of integrating multiomics analyses into practice can be addressed by involving proper management and sharing of data, collaboration among multiple stakeholders, the establishment and ongoing enhancement of standards, as well as the empowerment, education, and motivation of individuals. It is imperative to ensure equity, inclusion, and accessibility.

The exposome is a comprehensive framework that includes all physical, chemical, biological, and psychosocial factors, as well as their interactions, that influence biology and health [1]. It encompasses all environmental exposures throughout an individual's life, from pre-conception to death, that may affect health and disease outcomes. This concept also addresses multigenerational and transgenerational exposures, wherein environmental factors experienced by parents or grandparents may affect the health of future generations through mechanisms such as modifications in epigenetics, changes in maternal physiology, or heritable transmission of effects caused by environmental factors [2, 3].

Human disease development, progression, and various biological processes are due to a complex and rigorous interplay of molecular corrugations involving elements such as proteins, epigenetics, genetics, mRNA, etc., swayed by different environmental agents. Elements such as the human genome, epigenome, exposome, metabolome, transcriptome, and proteome can be measured at the individual level, facilitated by the advancement of technology; however, their interrelationship can be established by multi-omics data-driven studies. Gene-environment relations, molecular processes, and chronic disease progression can be better deciphered by assimilating multi-omics measurements into analyses. This integrative approach can enhance disease pathophysiology understanding in greater detail and unravel better strategies for prevention and precise treatment. Our review aims to extrapolate key building blocks of this approach.

Data sharing and management: sine qua non condition for today and tomorrow

The success of contemporary big data science depends on early and open sharing of scientific research, often beginning at the project's inception, leveraging extensive comprehensive datasets. To meet growing demands, it is essential to identify all functional genomic elements, along with their natural and pathological variations. These elements must be reliably linked to phenotypic traits to better understand biological processes and disease mechanisms, inform drug development, and address various health challenges. Research on the exposome builds upon genomic studies. Decoding the human genome has significantly enhanced our understanding of disease mechanisms. However, it is important to recognize that the genome represents just one aspect of the overall disease burden experienced by the population [4, 5].

Achieving this will require the sharing and enrichment of a diverse array of data, including individual genotype and phenotype information, at an exponentially larger scale (Fig. 1).

Data sharing principles and exchange platforms

The Global Alliance for Global Health (GA4GH) establishes principles and tools to support data sharing implementation. The GA4GH published the Framework for Responsible Sharing of Genomic and Health-Related Data in 2014, targeting regulators, funders, patient groups, IT professionals, industry representatives, publishers, and research consortia. This framework delineates the essential elements of responsible data sharing, which include transparency, accountability, recognition, attribution, and sanctions for misuse [6].

The eight Work Streams of GA4GH focus on developing policies and tools related to various issues such as ethical governance, consent, privacy, and security. The framework, translated into 14 languages, has shaped data-sharing policies globally [7]. Key functions of proper data governance encompass enabling data access, ensuring compliance with national laws and international agreements, supporting appropriate data usage and minimizing potential harms, promoting equity, and utilizing data for public benefit [8]. Proper governance is enhanced by the FAIR principles established in 2016 [9], which aim to make data Findable, Accessible, Interoperable, and Reusable for both humans and machines. These resources are often created by leading global scientific organizations and are supported by experts, including databases like OMIM, gnomAD, and PDB. Genomic commons—global repositories of accessible genomic data, including functional genomic elements and phenotypes [10]. Crowdsourcing platforms such as ClinVar, ClinGen, DECIPHER, and MatchMaker are




Fig. 1 Big data science success depends on leveraging extensive and comprehensive datasets as massive quantities of data are generated every second in both scientific and clinical contexts, accumulating in ever-expanding databases. To establish reference standards and control datasets that meet current demands, all functional elements of the genome along with their natural and pathological variations need to be identified and correlated these elements and their variants with phenotypic expressions, explore biological processes and disease mechanisms, develop effective medications, and tackle numerous other critical issues

democratizing data collection. DECIPHER—facilitates the sharing of diagnostic variants and phenotypic data from over 44,000 patients (as of 2023) [11].

In 2015, the MatchMaker Exchange (MME) was launched to unite eight existing platforms into a global resource that greatly enhances search efficiency. By 2022, the platform had recorded queries for over 13,520 genes and involved more than 12,000 medical professionals and scientists from 98 countries, resulting in over 120,000 case submissions. This initiative has enabled the identification of novel genetic disease genes and improved the diagnostic processes for patients with undiagnosed conditions [12]. Launched in 2013 by the National Human Genome Research Institute, the Clinical Genome Resource (ClinGen) is a collaborative effort with over 2,300 contributors from more than 67 countries (<https://www.clinicalgenome.org/>) [13].

Data accessibility

Data accessibility refers to the ease with which users can retrieve and obtain data without facing unnecessary obstacles. The General Data Protection Regulation (GDPR), which came into effect in 2018, particularly influences data sharing within the European Union (EU) and between the EU and other countries. While intended to harmonize data protection laws across the EU, the application of these regulations, especially concerning healthcare and research data, still brings about

considerable uncertainty [8]. Investigations into the GDPR's implementation have revealed that consent requirements, research exemptions, and the permissibility of international data transfers are interpreted differently by various institutions and countries [14]. For Europe to create a common European Health Data Space (EHDS) and actively engage in data-sharing-based science on a global level, it's crucial to establish clear legal frameworks and appropriate governance measures to ensure data interoperability [15]. Various initiatives are being developed to safeguard data in the context of worldwide sharing. Protecting privacy and security entails maintaining control over data, which has led to a decreased reliance on centralized data pooling. Instead, data can be stored in the cloud alongside the necessary methods, workflows, and computing resources, facilitating secure international access and large-scale analyses [15]. A growing trend is the federated approach, where independent organizations host data in secure, separate processing environments while implementing technical measures for large-scale sharing and analysis [16]. Application Programming Interfaces (APIs) allow researchers to access databases, even when different computing environments are in play [16]. Data accessibility can be further improved through the use of "beacons," which enable users to check the existence of specific genetic variants across multiple datasets and contact the relevant dataset controllers upon confirmation [17]. The GA4GH

is also developing shared data protection standards, such as the Data Use Ontology (DUO), which provides a clear, machine-readable standard language for consent forms and data sharing policies [18]. Additionally, the GA4GH Passport is being used to define user permissions for data access [19].

No datasets were generated or analysed during the current study.

Data accessibility is significantly improved through the integration of various databases and tools, which facilitate effective navigation of complex data environments, as exemplified by MARRVEL [20]. The growing trend of applying systematic methodologies to explore intricate biological phenomena necessitates the collaboration of diverse specialties and the amalgamation of various datasets. This trend underscores the increasing importance of consolidating different knowledge bases and databases into cohesive platforms that allow for a comprehensive examination of biological questions or processes from multiple perspectives.

Data interoperability

Data interoperability bolsters the effectiveness and integration of information across diverse systems and platforms. This endeavor is complex and involves the implementation of standardized, machine-readable data formats and protocols, controlled vocabularies, ontologies, and metadata schemas. Notable examples of widely adopted ontologies include the Human Phenotype Ontology (HPO) [21], Orphanet Rare Disease Ontology (ORDO; <https://www.orpha.net/>), OMIM Ontology [22], and Gene Ontology (GO) [23]. Additionally, new ontologies are being developed, such as the Medical Action Ontology (MAxO), which is specifically designed to systematically organize medical procedures, therapies, and interventions, in close relation to the Mondo Disease Ontology (Mondo) and the Human Phenotype Ontology (HPO) [24].

The FAIR principles have become a widely accepted standard for data management across various institutions and organizations, both nationally and internationally. A notable example is the Canadian Distributed Infrastructure for Genomics (CanDIG) platform, which facilitates federated querying and analysis of human genomics and linked biomedical data across ten Canadian provinces [25]. Similarly, the FAIR Genomes project in the Netherlands connects 14 medical centers and institutes, developing a shared semantic schema for essential data elements. This initiative has enabled the sharing of over 168,000 variant classifications, significantly enhancing variant interpretation [26]. For fairness and respect, it is essential to embrace both FAIR and CARE principles. Concerns from Indigenous peoples about secondary data use and limited benefit-sharing opportunities underscore

the tension between safeguarding Indigenous rights and supporting open data and big data initiatives. To address this, the International Indigenous Data Sovereignty Interest Group of the Research Data Alliance has developed the CARE Principles for Indigenous Data Governance (Collective Benefit, Authority to Control, Responsibility, and Ethics) in collaboration with Indigenous communities, scholars, non-profits, and governments [27]. These CARE Principles are focused on people and purpose, highlighting the significant role of data in advancing innovation, governance, and self-determination for Indigenous Peoples. They complement the existing data-centric FAIR principles, with the concepts of data FAIRification and CAREification being essential for enhancing efficiency, equity, and impact [28].

Standards and continuous cycles of quality improvement

Standards play a vital role in ensuring the accuracy and reliability of measurements, the reproducibility and credibility of methods, and the broader adoption of technologies. The creation of standards becomes necessary once sufficient data from a new method has been accumulated, enabling the identification of specific patterns. The International Rare Diseases Research Consortium (IRDIRC) has developed a quality label called "IRDIRC Recognized Resources" to highlight the standards, guidelines, tools, and platforms that should be utilized by those working in the rare disease research community [29]. In 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published guidelines that have been adopted globally for interpreting germline sequence variations. These guidelines recognized functional annotation as evidence of pathogenicity or benignity (PS3/BS3); however, the guidelines at that time were somewhat general concerning the application of functional criteria [30]. In 2019, ClinGen assessed the use of functional studies for six diseases, identifying several challenges and the need for clearer guidance to standardize the approach and ensure consistency in applying functional evidence [31]. The ClinGen Sequence Variant Interpretation (SVI) Working Group released recommendations in 2020, which included refined rules for assessing the clinical validity of functional data. These recommendations provide a four-step provisional framework to evaluate the strength of evidence from functional assays, covering aspects such as experimental design, replication, controls, and validation using human data [32]. ClinGen's Gene Curation Expert Panels conduct systematic evaluations and curate annotations of variants in clinically relevant genes, including assessments based on specialized functional assays [33]. The systematic integration of information from functional studies into public resources like the ClinVar

database would greatly enhance global efforts in variant assessment.

In addition, other standards play a crucial role in accurately assessing gene-disease associations and variant pathogenicity, resolving VUS, and identifying functional genomic elements [34]. This includes developing standards for various types of genetic variants and reanalyzing genomic testing results. As omics studies become more prevalent, recent recommendations have emerged to capture evidence regarding the predicted and observed impacts on splicing, including data from RNA-seq studies [35]. The Genomics Research to Elucidate the Genetics of Rare Diseases (GREGoR) Consortium has created criteria for triaging, sharing, and reporting novel candidate genes in clinical settings [36].

Environmental factors play a crucial role in shaping health outcomes, and their influence can differ significantly based on the specific condition being examined. In many cases, these factors can be as impactful as, or even more significant than, genetic influences. Understanding this relationship can lead to more effective health interventions and improvements in public health. Research shows that environmental factors are responsible for about 70–90% of the risk associated with chronic diseases such as cardiovascular disease and certain types of cancer. In contrast, a much smaller percentage is linked to inherited genetic variation. Therefore, it is crucial to evaluate the relative contributions of both environmental and genetic risk factors to model diseases and develop effective prevention strategies [37–40]

Communities brought together for common purposes: multi-stakeholder collaboration

The projects and initiatives outlined here span multiple biological fields and specialties, engaging diverse communities of stakeholders. The research conducted by these collaborative groups is crucial for uncovering the intricate biological makeup of humans in both health and disease. For current clinical practices, multi-stakeholder collaboration is vital to address complex diagnostic challenges and accommodate the diverse needs of people living with rare diseases (PLWRD).

In the United States, the Undiagnosed Disease Network (UDN) connects clinical centers with a Model Organism Screening Center (MOSC) to explore candidate genes and variants functionally. In Canada, the Rare Diseases Models and Mechanisms (RDMM) Network fosters collaborations between model organism researchers—represented by a registry of over 500 Canadian scientists with expertise in more than 7,500 human genes—and clinicians who have identified new disease gene variants. These partnerships not only validate variant pathogenicity but also elucidate the molecular mechanisms underpinning rare diseases (RD) and test new

therapies. Following this model, similar networks have emerged in Europe (Solve-RD—<http://solve-rd.eu/rdmm-europe/>), Australia (<https://www.functionalgenomics.org.au/>), Japan (<https://j-rdmm.org/indexEn.html>) and Singapore (Rare Disease Models and Mechanisms Network). Communication and collaboration have emerged as critical success factors across these initiatives. On a global level, collaborations between researchers and clinicians have been facilitated by ModelMatcher, which is part of the Matchmaker Exchange platform (<https://www.modelmatcher.net>), helping users identify potential partners. Additionally, the smooth integration of healthcare and research is supported by initiatives like NHS England's implementation of layered consent procedures within routine medical practice [7].

Exposomics is a field that utilizes high-throughput methodologies and employs a data-driven approach rather than a hypothesis-driven one. It integrates information from various methodologies and across different time points to thoroughly assess the impact of the exposome on health. This comprehensive analysis helps in evaluating risk and estimating the burden of environmental diseases. Additionally, exposomics seeks to uncover the cellular and molecular changes induced by the exposome, which can serve as potential biomarkers for diagnosis and create new opportunities for treatment [41].

The fundamental problems and solutions at the levels of all stakeholders is enumerated in Fig. 2.

Unfortunately, all too many RDs still suffer from a lack of foundational knowledge regarding their mechanisms, biomarker identification, and treatment development. Furthermore, the human genome and proteome contain many poorly studied or entirely uncharted areas. Currently, only 3% of the human proteome aligns with known drug targets linked through established mechanisms of action; an additional 6% bind to small molecules without such links. Meanwhile, 53% of proteins are connected to Mendelian diseases but lack further information necessary for clinical applications, and 38% are "dark" proteins, either minimally or not at all studied [42]. These categories include numerous potentially "druggable" proteins whose therapeutic prospects remain unexplored. Despite the surge of data from high-throughput omics studies and the rise of sophisticated computational resources, disparities in genome and proteome research, as well as functional annotation, continue and may even be worsening. Proteins that are well-researched are accumulating even more data, whereas others are experiencing stagnation in knowledge advancement. For instance, the widely studied p53 protein is featured in an average of two publications daily, while 95% of life science literature focuses on just 5,000 well-characterized human proteins [43]. Several factors contribute to the reluctance to




Fig. 2 Improving education and awareness of functional analysis across the continuum of care, from prevention to diagnosis, treatment and research including all relevant stakeholders (clinicians and healthcare providers, patients and caregivers, researchers, regulators and policy makers, funding agencies) is essential for addressing the challenges associated with RDs

explore these under-researched areas, including a lack of motivation driven by funding and prioritization norms, a tendency toward risk-averse, hypothesis-driven studies, career pressures for swift results, and misconceptions about the importance of frequently studied proteins. Other issues include inadequate promotion and awareness of understudied proteins, difficulties in accessing research tools and samples, and an over-reliance on standardized lab conditions that, while ensuring reproducibility, may impede innovation [44]. The vast potential of negative data remains largely untapped, despite attempts to shift traditional funding, prioritization, and publication practices. It typically takes 12 to 20 years for a human protein to garner enough information for clinical application. Breaking this cyclical pattern requires a collaborative approach among stakeholders, including targeted funding, training initiatives, incentives, and a unified effort to address research inequalities and bridge existing gaps [45].

Existing frameworks for data sharing

National plans and strategies are essential for fostering collaboration among multiple stakeholders and establishing shared responsibilities and accountability in the integration of genomic technologies into routine clinical practice. Numerous countries worldwide, including all EU nations except Malta and Sweden, as well as the UK, Switzerland, India, the Philippines, Japan, Australia,

Canada, Brazil, Chile, and South Africa, have implemented national RD plans [46, 47]. Although some of these have expired, they generally address key issues such as RD codification, registries, diagnostics and screening, orphan drug access, research, and patient support and empowerment. However, there is significant variability in the effectiveness of these plans; some lack multi-stakeholder collaboration, financial support mechanisms, or effective implementation. On the other hand, genomic medicine plans are more recent developments. The Global Genomic Medicine Collaborative (G2MC) was introduced in 2016 to drive the adoption of genomic medicine in clinical settings. Between 2017 and 2020, G2MC assessed 65 genomic medicine initiatives globally and found that the full integration of genomic medicine into standard health services remains relatively limited, with many projects primarily serving as pilot studies exploring implementation options. Most of these strategies emphasize genomic sequencing, data management, workforce training, ethical and social concerns, and raising public awareness [48]. Insights from the National Human Genome Research Institute's (NHGRI) Implementing GeNomics In pracTice (IGNITE) Network study indicated that key factors driving implementation included genomic clinical decision support tools within the electronic health record (EHR) and third-party reimbursement for genomic testing [49]. IRDIRC Functional

Analyses task force recommends the collaboration framework as outlined in Fig. 3.

In Europe, several prominent institutions and collaborative projects are dedicated to advancing our understanding of the exposome and its impact on health. Notable entities include Helmholtz Munich [50] and initiatives such as the Enhanced Exposure Assessment and Omic Profiling for High-Priority Environmental Exposures in Europe (EXPOsOMICS) [51] and the European Human Exposome Network (EHEN) [52]. The HERCULES Exposome Research Center [53] and the Institute for Exposomic Research at Mount Sinai [54] in the United States are contributing exposome research significantly. Exposomics is advancing rapidly due to significant technological developments in genetic and omics technologies, along with big data analytics [55]. The exposome influences various omics layers and is crucial in understanding disease etiology [56].

Exposomics focuses on measuring environmental exposures and their biological responses. The approach employs a diverse range of tools and methodologies, including omics technologies, sensors, mobile devices and applications, geospatial devices, and self-reported questionnaire responses, which are aptly facilitated by statistical and bioinformatics tools. This combination enables comprehensive data collection and analysis, enhancing our understanding of complex biological systems and their interactions in various environments [57].

Empowered, educated and motivated people—the main driver forward

Education and training serve as vital instruments for empowering multi-stakeholder communities within the functional genomics ecosystem. This ecosystem encompasses a range of participants, including researchers, healthcare providers, allied professionals, funders, regulators, and patient representatives. The educational needs of these groups are diverse, requiring content that spans from basic information to highly specialized knowledge, and formats that range from traditional lectures and Massive Open Online Course (MOOCs) to hands-on training and mentoring programs. It is essential for all medical and specialty students, as well as the current healthcare workforce, to receive education in RDs and genomics. Professional organizations play a crucial role in establishing practice standards and educational goals, as well as providing ongoing professional training and medical education. It is essential that these organizations acknowledge the significance of RD and genomics education, integrating these topics into their agendas [58]. To enhance the diagnosis of RDs, all healthcare providers must be able to identify potential signs—known as red flags—that necessitate referrals for specialized genetic diagnosis. Translating these red flags into various languages, including Indigenous languages like those developed by Lyfe Languages (<https://www.lyfelanguages.com>), is critical for promoting equity and inclusion. For individuals involved in genetic diagnostic services,




Fig. 3 Best practices collaboration model recommendation by IRDIRC Functional Analyses task force for global adaptation




Fig. 4 With patient as the core of all initiatives towards skill enhancement for healthcare professionals it is essential that an integrated approach towards education and training with patient registries and data networks coupled with collaborative efforts built at grassroots, country and international level could be gamechanger for all stakeholders

understanding the principles of genomic variant analysis and interpretation, genetic counselling, and the associated ethical and legal challenges is paramount [59].

Key sources of this knowledge and training include European Reference Networks [60], international initiatives, infrastructures, and programs like the European Joint Programme on Rare Diseases (<https://www.ejprarediseases.org/>), ELIXIR [61], and the Global Nursing Network for Rare Diseases (<https://www.gnnrd.org/>), along with other global organizations [62]. Training is typically created by international experts and offered to a worldwide audience, highlighting the significance of online training formats that enhance access to specialized knowledge. The global interest in these webinars organized by European Reference Networks [63] underscores the importance of such educational opportunities. Care coordinators and case managers can improve access to RD diagnostics while bioinformatics and computational science specialists have become crucial members of genomic diagnostics teams. Additionally, data stewards and data managers play a vital role in ensuring the proper management and FAIRification of data. To

tackle the complexities of emerging fields like functional genomics, knowledge in systems biology is increasingly being offered through master's programs. It is crucial to establish training objectives for these new fields, develop corresponding programs, and implement them in universities and educational institutions (Fig. 4) with active collaborations.

For years, successful training programs have been conducted by international patient organizations, including EURORDIS Open Academy, EUPATI, NORD, GARD, and NCATS [64]. These programs often include both patient representatives and researchers, which helps to promote mutual understanding and collaboration. However, it is crucial that training initiatives are also disseminated at the national level, ensuring they reach patient representatives through appropriate formats, such as simplified and visual resources, while accounting for multicultural, linguistic, and ethnic differences [65]. To promote equity and inclusivity for underrepresented populations, educational resources should be tailored to resonate with specific communities. For example, the Aboriginal Australian concept of songlines and their

singers has been used effectively to explain inheritance concepts and their relation to health. Cross-cultural narratives, like basket weaving, could also serve as useful avenues for conveying complex ideas related to genomic or functional analysis (<https://www.lyfelanguages.com/>). Furthermore, the Lyfe Languages initiative, a universal Indigenous medical translator project, is paving the way for technological solutions that include translations and educational resources for both clinicians and patients.

Exposome-wide association studies (ExWAS) are a data-driven logical architecture designed for large-scale exploratory studies in exposomics, applicable across various study designs, including cohort, cross-sectional, longitudinal, and case-control studies. The approach emphasizes interpretability and can utilize a range of methods grounded in regression and other statistical techniques. The core objective of ExWAS is to systematically reproduce all paired relationships between a single phenotype and numerous exposures, aiming to identify statistically significant associations while accounting for multiple analogies [66]. For instance, ExWAS has been deployed to investigate the association of 266 environmental factors with type 2 diabetes, revealing both risk factors (such as heptachlor epoxide) and protective factors (such as β -carotenes) [67].

Empowering patients effectively goes beyond offering training in leadership, advocacy, and general knowledge. It also encompasses education on all critical aspects of research and the application of innovations. This includes integrating patients into joint scientific projects, especially those addressing socioeconomic and clinical issues, as well as supporting RD research through non-governmental organizations and foundations. Patient advocacy groups play a pivotal role in this process, serving as bridges between researchers, clinicians, and the patient community, and ensuring that research agendas align with patients' real-world needs. Additionally, patient representatives are encouraged to take part in the translation of innovations, contributing to bioethical and regulatory committees, such as those at the European Medicines Agency, and participating in healthcare organization decisions, like those in hospital boards or national oversight committees for RDs.

Equity, diversity and inclusion

The opportunities available for PLWRD as well as for healthcare providers and researchers working in the field, are neither equal nor fair. A variety of factors contribute to these inequities, including financial constraints, cultural differences, language barriers, workforce shortages, stigma, and more [68]. Millions of individuals around the world suffer from undiagnosed RDs, not due to a lack of diagnostic technology, but because of the limited availability of modern and effective (genomic)

diagnostic methods [69] and insufficient resources hindering the capacity to exchange crucial genomic and clinical data [7]. Additionally, public genomic databases like gnomAD are often unrepresentative of many populations, particularly those from African, Middle Eastern, and Oceanian communities, resulting in patients having rarer VUSs [70]. Although individuals of European descent account for around 16% of the global population, most of the genomic research originates from people of European ancestry [71]. This lack of representation exacerbates diagnostic uncertainty and delays access to appropriate treatments, particularly for historically marginalized populations. Fortunately, this gap can be partially addressed through unbiased high-throughput methods such as MAVE [72] and computational resources like AlphaFold [73], which offer functionally relevant information beneficial to communities worldwide. Genomic research in high-income countries often fails to adequately include participants from underrepresented communities, including rural populations and those from culturally and linguistically diverse backgrounds, unless specific steps toward inclusivity are taken [74]. Intentional efforts must be made to improve recruitment, community engagement, and culturally adapted informed consent processes to ensure that diverse populations are equitably represented in research. Initiatives aimed at enhancing representation include the Australian Indigenous Genomics Network (ALIGN), which features a Rare Diseases Flagship and focuses on functional analysis, as well as Australian Genomics projects that actively involve Aboriginal and Torres Strait Islander populations [75]. gnomAD has also made calls to increase genetic diversity in population-scale datasets [76]. Open-source tools provided by global genomic databases, such as the DECIPHER system, assist in data sharing and collaboration, with platforms like DDD-Africa (<https://h3africa.org/index.php/ddd-africa>) utilizing these resources [11].

Collaboration among resource-limited countries and global partnerships is crucial. While individual African or low-income Asian nations may lack national genomic medicine programs, multinational initiatives like the Human Heredity and Health in Africa (H3Africa) consortium (<https://h3africa.org/>) and the GenomeAsia 100 K consortium (<https://genomeasia100k.org>) promote the advancement of genomic medicine [48]. The H3Africa initiative aims to encourage research relevant to African contexts while building capacity for genomic research. It focuses on collecting and processing genomic and clinical data associated with various non-communicable and infectious diseases, creating high-quality biorepositories, and developing a bioinformatics network while offering training programs for healthcare professionals and researchers [77]. Another global partnership, the International Centre for Genomic Medicine in Neuromuscular

Diseases (ICGNMD) initiated to enhance the diagnosis of hereditary neuromuscular diseases, is a network of 18 centers across Brazil, India, South Africa, Turkey, Zambia, the Netherlands, and the UK. This centre collaborated to develop a cloud-based data solution, trained 17 international neurology fellows in clinical genomic data interpretation, and provided genomic diagnostics to thousands of NMD patients from understudied populations [78]. The Undiagnosed Diseases Network International connects centers worldwide to improve the diagnosis of RDs [79] and comprises active functional analysis and low- and middle-income country working groups. The GA4GH has established global standards for genomic equity, diversity, and inclusion, forming specialized groups focused on equity, diversity, and regulatory and ethical considerations [71].

Translational science related to exposomics can provide valuable insights for shaping public health policies and discourse aimed at reducing population-level risks and guiding essential regulatory actions. [80] Exposomics focuses on identifying environmental risks that impact specific population groups, allowing policymakers to concentrate with meaningful interventions on high-risk groups or areas [81]. This approach facilitates the development and implementation of focused regulations that take into consideration various factors influencing health risks [81]. Data derived from exposome studies can influence policies related to chemical exposure [82], air quality [51], and workplace safety [83]. Even though individuals with the same syndromic form of intellectual developmental disability (IDD) share the same genetic background, there is significant variability in their cognitive abilities and IQ scores. Research suggests that almost 80% of the differences in IQ among those with syndromic IDDs can be linked to non-genetic factors such as exposomes [84].

Conclusion

To successfully integrate functional multi-omics analyses into routine healthcare, it is imperative to focus on several key areas: establishing robust data sharing and management practices, adhering to standards with continuous improvements, fostering collaboration among various stakeholders, and empowering individuals through education and motivation. By ensuring data accessibility, interoperability, and reusability, along with the formation of international partnerships and the implementation of equitable, inclusive measures, we can maximize the potential of multi-omics technologies to enhance diagnostics and patient care for PLWRD. These efforts will contribute to the creation of a more efficient and comprehensive healthcare system that leverages the latest genomic advancements to address complex medical challenges and leverage precision medicine.

Acknowledgements

Dr Suchitra Kataria of Melange Communications Pte Ltd, Singapore, provided the medical writing support.

Author contributions

All the authors contributed equally to the writing, reviews and editing process of the manuscript.

Funding

The IRDiRC Functional Analysis Task Force was supported by the Scientific Secretariat of IRDiRC, funded by the European Union through the European Joint Programme on Rare Diseases (EJP RD) under the European Union's Horizon 2020 Research and Innovation Programme Grant Agreement N°825575.

Declarations

Ethics approval and consent to participate

This review does not contain any studies with human subjects performed by any of the authors.

Competing interests

SSJ is supported by National Medical Research Council Clinician Scientist Award (NMRC/CSAINVJun21-0003) and (NMRC/CSAINV24jul-0001). SSJ is co-founder of Global Gene Corp Pte Ltd and Rhea Health Pte Ltd. RML was supported by the Intramural Research Program of the National Institutes of Health (NIH). The contributions of the NIH author(s) are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services. Rest of the authors declare no conflict of interest involved.

Author details

¹Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania

²National Human Genome Research Institute, National Institutes of Health, Bethesda, USA

³Sage Bionetworks, Seattle, USA

⁴Institute of Rare Diseases Research (IIR), Spanish National Institute of Health Carlos III (ISCIII), Madrid, Spain

⁵Sanford Research, Sioux Falls, USA

⁶Laboratorio de Genética y Enfermedades Metabólicas, Instituto de Nutrición y Tecnología de los Alimentos, Universidad de Chile, Santiago, Chile

⁷The Kids Research Institute Australia, Nedlands, Australia

⁸Chan Zuckerberg Initiative, Redwood City, CA, USA

⁹EURORDIS, Rare Diseases Europe, Paris, France

¹⁰SingHealth Duke-NUS Institute of Precision Medicine, Singapore, Singapore

¹¹Department of Family Medicine, Mayo Clinic, Rochester, MN, USA

¹²KK Women's and Children's Hospital, Singapore, Singapore

¹³IRDiRC Scientific Secretariat, French National Institute of Health and Medical Research (Inserm), Ivry-sur-Seine, France

¹⁴National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Maryland, USA

¹⁵Sir Ganga Ram Hospital, New Delhi, India

¹⁶Australian Institute of Tropical Health and Medicine, James Cook University, Douglas, Australia

¹⁷The Scojen Institute for Synthetic Biology, Reichman University, Herzliya, Israel

¹⁸Biomedical and Molecular Metabolism Research (BioMMet), North-West University, Potchefstroom, South Africa

¹⁹Genes and Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, USA

²⁰Baylor College of Medicine, Houston, USA

²¹Rare Care Centre, Perth Children's Hospital and Western Australian Register of Developmental Anomalies, King Edward Memorial Hospital, Subiaco, Australia

²²Agency for Science, Technology and Research (A*STAR), Bioinformatics Institute (BII), Singapore, Singapore

Received: 24 June 2025 / Accepted: 22 December 2025

Published online: 25 March 2026

References

- Wild CP. Complementing the Genome with an “Exposome”: The Outstanding Challenge of Environmental Exposure Measurement in Molecular Epidemiology. *Cancer Epidemiol Biomarkers Prev*. 2005;14(8):1847–50. <https://doi.org/10.1158/1055-9965.EPI-05-0456>.
- Gaspari L, Paris F, Kalfa N, Soyser-Gobillard MO, Sultan C, Hamamah S. Experimental evidence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) transgenerational effects on reproductive health. *Int J Mol Sci*. 2021;22(16):9091. <https://doi.org/10.3390/ijms22169091>.
- Coperchini F, Teliti M, Greco A, Croce L, Rotondi M. Per-polyfluoroalkyl substances (PFAS) as thyroid disruptors: is there evidence for multi-transgenerational effects? *Expert Rev Endocrinol Metab*. 2024;19(4):307–15. <https://doi.org/10.1080/17446651.2024.2351885>.
- Schmutz J, Wheeler J, Grimwood J, Dickson M, Yang J, Caoile C, et al. Quality assessment of the Human Genome Sequence. *Nature*. 2004;429(6990):365–8. <https://doi.org/10.1038/nature02390>.
- Counil E. Contribution of causal factors to disease burden: how to interpret attributable fractions. *Breathe*. 2021;17(4):210086. <https://doi.org/10.1183/20734735.0086-2021>.
- Knoppers BM. Framework for responsible sharing of genomic and health-related data. *Hugo J*. 2014;8(1):3. <https://doi.org/10.1186/s11568-014-0003-1>.
- Rehm HL, Page AJH, Smith L, Adams JB, Alterovitz G, Babb LJ, et al. GA4GH: international policies and standards for data sharing across genomic research and healthcare. *Cell Genom*. 2021;1(2):100029. <https://doi.org/10.1016/j.xgen.2021.100029>.
- O'Doherty KC, Shabani M, Dove ES, Bentzen HB, Borry P, Burgess MM, et al. Toward better governance of human genomic data. *Nat Genet*. 2021;53(1):2–8. <https://doi.org/10.1038/s41588-020-00742-6>.
- Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, Blomberg N, Boiten JW, da Silva Santos LB, Bourne PE, Bouwman J, Brookes AJ, Clark T, Crosas M, Dillo I, Dumon O, Edmunds S, Evelo CT, Finkers R, Gonzalez-Beltran A, Gray AJ, Groth P, Goble C, Grethe JS, Heringa J, 't Hoen PA, Hoofstede R, Kuhn T, Kok R, Kok J, Lusher SJ, Martone ME, Mons A, Packer AL, Persson B, Rocca-Serra P, Roos M, van Schaik R, Sansone SA, Schultes E, Sengstag T, Slater T, Strawn G, Swertz MA, Thompson M, van der Lei J, van Mulligen E, Velterop J, Waagmeester A, Wittenburg P, Wolstencroft K, Zhao J, Mons B. The FAIR Guiding Principles for scientific data management and stewardship. *Sci Data*. 2016;3:160018. Erratum in: *Sci Data*. 2019;6(1):6.
- Contreras JL, Knoppers BM. The Genomic Commons. *Annu Rev Genomics Hum Genet*. 2018;19(1):429–53. <https://doi.org/10.1146/annurev-genom-083117-021552>.
- Foreman J, Perrett D, Mazaika E, Hunt SE, Ware JS, Firth HV. DECIPHER: improving genetic diagnosis through dynamic integration of genomic and clinical data. *Annu Rev Genomics Hum Genet*. 2023;24:151–76. <https://doi.org/10.1146/annurev-genom-102822-100509>.
- Boycott KM, Azzariti DR, Hamosh A, Rehm HL. Seven years since the launch of the Matchmaker Exchange: the evolution of genomic matchmaking. *Hum Mutat*. 2022;43(6):659–67. <https://doi.org/10.1002/humu.24373>.
- Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al. ClinGen—the clinical genome resource. *N Engl J Med*. 2015;372(23):2235–42. <https://doi.org/10.1056/NEJMs1406261>.
- Bentzen HB, Castro R, Fears R, Griffin G, Ter Meulen V, Ursin G. Remove obstacles to sharing health data with researchers outside of the European Union. *Nat Med*. 2021;27(8):1329–33. <https://doi.org/10.1038/s41591-021-01460-0>.
- Thorogood A, Rehm HL, Goodhand P, Page AJH, Joly Y, Baudis M, et al. International federation of genomic medicine databases using GA4GH standards. *Cell Genom*. 2021;1(2):100032. <https://doi.org/10.1016/j.xgen.2021.100032>.
- Overkleeft R, Tommel J, Evers AWM, den Dunnen JT, Roos M, Hoefmans MJ, et al. Using personal genomic data within primary care: a bioinformatics approach to pharmacogenomics. *Genes*. 2020;11(12):1443. <https://doi.org/10.3390/genes11121443>.
- Saunders G, Baudis M, Becker R, Beltran S, Bérout C, Birney E, Brooksbank C, Brunak S, Van den Bulcke M, Drysdale R, Capella-Gutierrez S, Flicek P, Florindi F, Goodhand P, Gut I, Heringa J, Holub P, Hooyberghs J, Juty N, Keane TM, Korbelt JO, Lappalainen I, Leskosek B, Matthijs G, Mayrhofer MT, Metspalu A, Navarro A, Newhouse S, Nyronen T, Page A, Persson B, Palotie A, Parkinson H, Rambla J, Salgado D, Steinfelder E, Swertz MA, Valencia A, Varma S, Blomberg N, Scollen S. Leveraging European infrastructures to access 1 million human genomes by 2022. *Nat Rev Genet*. 2019;20(11):693–701. Epub 2019 Aug 27. Erratum in: *Nat Rev Genet*. 2019 Nov;20(11):702.
- Lawson J, Cabili MN, Kerry G, Boughtwood T, Thorogood A, Alper P, Bowers SR, Boyles RR, Brookes AJ, Brush M, Burdett T, Clissold H, Donnelly S, Dyke SOM, Freeberg MA, Haendel MA, Hata C, Holub P, Jeanson F, Jene A, Kawashima M, Kawashima S, Konopko M, Kyomugisha I, Li H, Linden M, Rodriguez LL, Morita M, Mulder N, Muller J, Nagaie S, Nasir J, Ogishima S, Ota Wang V, Paglione LD, Pandya RN, Parkinson H, Philippakis AA, Prasser F, Rambla J, Reinold K, Rushton GA, Saltzman A, Saunders G, Sofia HJ, Spalding JD, Swertz MA, Tulchinsky I, van Enckevort EJ, Varma S, Voisin C, Yamamoto N, Yamasaki C, Zass L, Guidry Auvil JM, Nyronen TH, Courtot M. The Data Use Ontology to streamline responsible access to human biomedical datasets. *Cell Genom*. 2021;1(2):None. <https://doi.org/10.1016/j.xgen.2021.100028>.
- Voisin C, Linden M, Dyke SOM, Bowers SR, Alper P, Barkley MP, Bernick D, Chao J, Courtot M, Jeanson F, Konopko M, Kuba M, Lawson J, Leinonen J, Li S, Ota Wang V, Philippakis AA, Reinold K, Rushton GA, Spalding JD, Törnroos J, Tulchinsky I, Guidry Auvil JM, Nyronen TH. GA4GH Passport standard for digital identity and access permissions. *Cell Genom*. 2021;1(2):None. <https://doi.org/10.1016/j.xgen.2021.100030>.
- Wang J, Al-Ouran R, Hu Y, Kim SY, Wan YW, Wangler MF, Yamamoto S, Chao HT, Comjean A, Mohr SE, UDN; Perrimon N, Liu Z, Bellen HJ. MARRVEL: Integration of Human and Model Organism Genetic Resources to Facilitate Functional Annotation of the Human Genome. *Am J Hum Genet*. 2017;100(6):843–853. <https://doi.org/10.1016/j.ajhg.2017.04.010>.
- Gargano MA, Matentzoglou N, Coleman B, Addo-Lartey EB, Anagnostopoulos AV, Anderton J, Avillach P, Bagley AM, Bakstein E, Balhoff JP, Baynam G, Bello SM, Berk M, Bertram H, Bishop S, Blau H, Bodenstien DF, Botas P, Boztug K, Cady J, Callahan TJ, Cameron R, Carbon SJ, Castellanos F, Caulfield JH, Chan LE, Chute CG, Cruz-Rojas J, Dahan-Oliel N, Davids JR, de Dieuleveult M, de Souza V, de Vries BBA, de Vries E, DePaulo JR, Derfalvi B, Dhombres F, Diaz-Byrd C, Dingemans AJM, Donadille B, Duyzend M, Elfeky R, Essaid S, Fabrizio C, Fico G, Firth HV, Freudenberg-Hua Y, Fullerton JM, Gabriel DL, Gilmour K, Giordano J, Goes FS, Moses RG, Green I, Griesse M, Groza T, Gu W, Guthrie J, Gyori B, Hamosh A, Hanauer M, Hanušová K, He YO, Hegde H, Helbig I, Holasová K, Hoyt CT, Huang S, Hurwitz E, Jacobsen JOB, Jiang X, Joseph L, Keramatian K, King B, Knoflach K, Koolen DA, Kraus ML, Kroll C, Kusters M, Ladewig MS, Lagorce D, Lai MC, Lapunzina P, Laraway B, Lewis-Smith D, Li X, Lucano C, Majd M, Marazita ML, Martinez-Glez V, McHenry TH, McInnis MG, McMurry JA, Mihulová M, Millett CE, Mitchell PB, Moslerová V, Narutomi K, Nematollahi S, Nevado J, Nierenberg AA, Čajbiková NN, Nurnberger JJ Jr, Ogishima S, Olson D, Ortiz A, Pachajoa H, Perez de Nancres G, Peters A, Putman T, Rapp CK, Rath A, Reese J, Rekerle L, Roberts AM, Roy S, Sanders SJ, Schuetz C, Schulte EC, Schulze TG, Schwarz M, Scott K, Seelow D, Seitz B, Shen Y, Similuk MN, Simon ES, Singh B, Smedley D, Smith CL, Smolinsky JT, Sperry S, Stafford E, Stefancsik R, Steinhaus R, Strawbridge R, Sundaramurthi JC, Talapova P, Tenorio Castano JA, Tesner P, Thomas RH, Thurm A, Turnovec M, van Gijn ME, Vasilevsky NA, Vlčková M, Walden A, Wang K, Wapner R, Ware JS, Wafae AA, Wafae SA, Wiggins LD, Williams AE, Wu C, Wyrwoll MJ, Xiong H, Yalin N, Yamamoto Y, Yatham LN, Yocum AK, Young AH, Yüksel Z, Zandi PP, Zankl A, Zarante I, Zvolský M, Toro S, Carmody LC, Harris NL, Munoz-Torres MC, Danis D, Mungall CJ, Köhler S, Haendel MA, Robinson PN. The Human Phenotype Ontology in 2024: phenotypes around the world. *Nucleic Acids Res*. 2024;52(D1):D1333–D1346. <https://doi.org/10.1093/nar/gkad1005>.
- Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. *Nucleic Acids Res*. 2015;43(Database issue):D789–98. <https://doi.org/10.1093/nar/gku1205>.
- Gene Ontology Consortium; Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, Ebert D, Feuermann M, Gaudet P, Harris NL, Hill DP, Lee R, Mi H, Moxon S, Mungall CJ, Muruganugan A, Mushayahama T, Sternberg PW, Thomas PD, Van Auken K, Ramsey J, Siegle DA, Chisholm RL, Fey P, Aspromonte MC, Nugnes MV, Quaglia F, Tosatto S, Giglio M, Nadendla S, Antonazzo G, Attrill H, Dos Santos G, Marygold S, Strelets V, Tabone CJ, Thurmond J, Zhou P, Ahmed SH, Asanithong P, Luna Buitrago D, Erdol MN, Gage MC, Ali Kadhun M, Li KYC, Long M, Michalak A, Pesala A, Pritazhara A, Saverimuttu SCC, Su R, Thurlow KE, Lovering RC, Logie C, Oliferenko S, Blake J, Christie K, Corbani L, Dolan ME, Drabkin HJ, Hill DP, Ni L, Sitnikov D, Smith C, Cuzick A, Seager J, Cooper L, Elser J, Jaiswal P, Gupta P, Jaiswal P, Naithani S, Lera-Ramirez M, Rutherford K, Wood V, De Pons JL, Dwinell MR, Hayman GT, Kaldunski ML, Kwitek AE, Laulederkind SJF, Tutaj MA, VEDI M, Wang SJ,

- D'Eustachio P, Aimò L, Axelsen K, Bridge A, Hyka-Nouspikel N, Morgat A, Aleksander SA, Cherry JM, Engel SR, Karra K, Miyasato SR, Nash RS, Krzypek MS, Weng S, Wong ED, Bakker E, Berardini TZ, Reiser L, Auchincloss A, Axelsen K, Argoud-Puy G, Blatter MC, Boutet E, Breuza L, Bridge A, Casals-Casas C, Coudert E, Estreicher A, Livia Famiglietti M, Feuermann M, Gos A, Gruaz-Gumowski N, Hulo C, Hyka-Nouspikel N, Jungo F, Le Mercier P, Lieberherr D, Masson P, Morgat A, Pedruzzi I, Pourcel L, Poux S, Rivoire C, Sundaram S, Bateman A, Bowler-Barnett E, Bye-A-Jee H, Denny P, Ignatchenko A, Ishtiaq R, Lock A, Lussi Y, Magrane M, Martin MJ, Orchard S, Raposo P, Speretta E, Tyagi N, Warner K, Zaru R, Diehl AD, Lee R, Chan J, Diamantakis S, Raciti D, Zarowiecki M, Fisher M, James-Zorn C, Ponferrada V, Zorn A, Ramachandran S, Ruzicka L, Westerfield M. The Gene Ontology knowledgebase in 2023. *Genetics*. 2023;224(1):iyad031. <https://doi.org/10.1093/genetics/iyad031>.
24. Carmody LC, Gargano MA, Toro S, Vasilevsky NA, Adam MP, Blau H, et al. The medical action ontology: a tool for annotating and analyzing treatments and clinical management of human disease. *Med*. 2023;4(12):913–927.e3. <https://doi.org/10.1016/j.medj.2023.10.003>.
25. Dursi LJ, Bozoky Z, de Borja R, Li H, Bujold D, Lipski A, et al. CanDIG: federated network across Canada for multi-omic and health data discovery and analysis. *Cell Genomics*. 2021;1(2):100033. <https://doi.org/10.1016/j.xgen.2021.100033>.
26. van der Velde KJ, Singh G, Kaliyaperumal R, Liao X, de Ridt S, Rebers S, et al. Fair genomes metadata schema promoting Next Generation Sequencing data reuse in Dutch healthcare and research. *Sci Data*. 2022;13(9):169. <https://doi.org/10.1038/s41597-022-01265-x>.
27. Carroll SR, Herczog E, Hudson M, Russell K, Stall S. Operationalizing the CARE and FAIR principles for Indigenous data futures. *Sci Data*. 2021;8(1):108. <https://doi.org/10.1038/s41597-021-00892-0>.
28. Carroll SR, Plevel R, Jennings LL, Garba I, Sterling R, Cordova-Marks FM, et al. Extending the CARE principles from tribal research policies to benefit sharing in genomic research. *Front Genet*. 2022;13:1052620. <https://doi.org/10.3389/fgenet.2022.1052620>.
29. Lochmüller H, Le Cam Y, Jonker AH, Lau LP, Baynam G, Kaufmann P, et al. "IRDIRC Recognized Resources": a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases. *Eur J Hum Genet*. 2017;25(2):162–5. <https://doi.org/10.1038/ejhg.2016.137>.
30. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405–24. <https://doi.org/10.1038/gim.2015.30>.
31. Kanavy DM, McNulty SM, Jairath MK, Brnich SE, Bizon C, Powell BC, et al. Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels. *Genome Med*. 2019;11(1):77. <https://doi.org/10.1186/s13073-019-0683-1>.
32. Brnich SE, Abou Tayoun AN, Couch FJ, Cutting GR, Greenblatt MS, Heinen CD, et al. Recommendations for application of the functional evidence P53/B53 criterion using the ACMG/AMP sequence variant interpretation framework. *Genome Med*. 2019. <https://doi.org/10.1186/s13073-019-0690-2>.
33. Rivera-Muñoz EA, Milko LV, Harrison SM, Azzariti DR, Kurtz CL, Lee K, et al. ClinGen Variant Curation Expert Panel experiences and standardized processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence variant interpretation. *Hum Mutat*. 2018;39(11):1614–22. <https://doi.org/10.1002/humu.23645>.
34. Deignan JL, Chung WK, Kearney HM, Monaghan KG, Rehder CW, Chao EC, et al. Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2019;21(6):1267–70. <https://doi.org/10.1038/s41436-019-0478-1>.
35. Walker LC, Hoya M, Wiggins GAR, Lindy A, Vincent LM, Parsons MT, et al. Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: recommendations from the ClinGen SVI Splicing Subgroup. *Am J Hum Genet*. 2023. <https://doi.org/10.1016/j.ajhg.2023.06.002>.
36. Chong JX, Berger SI, Baxter S, Smith E, Xiao C, Calame DG, et al. Considerations for reporting variants in novel candidate genes identified during clinical genomic testing. *Genet Med*. 2024;26(10):101199. <https://doi.org/10.1016/j.gim.2024.101199>.
37. Counil E. Contribution of causal factors to disease burden: how to interpret attributable fractions. *Breathe (Sheff)*. 2021;17(4):210086. <https://doi.org/10.1183/20734735.0086-2021>.
38. Smith KR, Corvalán CF, Kjellström T. How much global ill health is attributable to environmental factors? *Epidemiology*. 1999;10(5):573–84.
39. Rappaport SM. Discovering environmental causes of disease. *J Epidemiol Community Health*. 2012;66(2):99–102. <https://doi.org/10.1136/jech-2011-200726>.
40. Rappaport SM, Smith MT. Environment and disease risks. *Science*. 2010;330(6003):460–1. <https://doi.org/10.1126/science.1192603>.
41. Steckling N, Gotti A, Bose-O'Reilly S, Chapizanis D, Costopoulou D, De Vocht F, et al. Biomarkers of exposure in environment-wide association studies - opportunities to decode the exposome using human biomonitoring data. *Environ Res*. 2018;164:597–624. <https://doi.org/10.1016/j.envres.2018.02.041>.
42. Oprea TI, Bologa CG, Brunak S, Campbell A, Gan GN, Gaulton A, et al. Unexplored therapeutic opportunities in the human genome. *Nat Rev Drug Discov*. 2018;17(5):317–32. <https://doi.org/10.1038/nrd.2018.14>.
43. Kustatscher G, Collins T, Gingras AC, Guo T, Hermjakob H, Ideker T, et al. Understudied proteins: opportunities and challenges for functional proteomics. *Nat Methods*. 2022;19(7):774–9. <https://doi.org/10.1038/s41592-022-01454-x>.
44. Wood V, Lock A, Harris MA, Rutherford K, Bähler J, Oliver SG. Hidden in plain sight: what remains to be discovered in the eukaryotic proteome? *Open Biol*. 2019;9(2):180241. <https://doi.org/10.1098/rsob.180241>.
45. de Crécy-Lagard V, de Amorin Hegedus R, Arighi C, Babor J, Bateman A, Blaby I, et al. A roadmap for the functional annotation of protein families: a community perspective. *Database (Oxford)*. 2022;12:2022.baac062. <https://doi.org/10.1093/database/baac062>.
46. Hedley V, Bottarelli V, Weinman A, Taruscio D. Shaping national plans and strategies for rare diseases in Europe: past, present, and future. *J Community Genet*. 2021;12(2):207–16. <https://doi.org/10.1007/s12687-021-00525-4>.
47. Khosla N, Valdez R. A compilation of national plans, policies and government actions for rare diseases in 23 countries. *Intractable & Rare Diseases Research*. 2018;7(4):213–22. <https://doi.org/10.5582/irdr.2018.01085>.
48. Belcher A, Ginsburg GS, Ward R. Global approaches to genomic medicine implementation. *Sci Transl Med*. 2020;12(563):eaax0911. <https://doi.org/10.1126/scitranslmed.aax0911>.
49. Levy KD, Blake K, Fletcher-Hoppe C, Franciosi J, Goto D, Hicks JK, et al. Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network. *Genet Med*. 2019;21(3):743–7. <https://doi.org/10.1038/s41436-018-0080-y>.
50. Helmholtz Munich. Exposomics. <https://www.helmholtz-munich.de/en/epi/research-groups/exposomics>
51. Vineis P, Chadeau-Hyam M, Gmuender H, Gulliver J, Herczeg Z, Kleinjans J, et al. The exposome in practice: design of the EXPOsOMICS project. *Int J Hyg Environ Health*. 2017;220(2 Pt A):142–51. <https://doi.org/10.1016/j.ijheh.2016.08.001>.
52. Fayet Y, Bonnin T, Canali S, Giroux E. Putting the exposome into practice: an analysis of the promises, methods and outcomes of the European human exposome network. *Soc Sci Med*. 2024;354:117056. <https://doi.org/10.1016/j.socscimed.2024.117056>.
53. NIH-Funded Environmental Health Sciences Core Center. Hercules Exposome Research Center. 2024. <https://emoryhercules.com>
54. Institute for Climate Change, Environmental Health, and Exposomics. Ichan School of Medicine at Mount Sinai 2024.
55. Vermeulen R, Schymanski EL, Barabási AL, Miller GW. The exposome and health: where chemistry meets biology. *Science*. 2020;367(6476):392–6. <https://doi.org/10.1126/science.aay3164>.
56. Wu H, Eckhardt CM, Baccarelli AA. Molecular mechanisms of environmental exposures and human disease. *Nat Rev Genet*. 2023;24(5):332–44. <https://doi.org/10.1038/s41576-022-00569-3>.
57. Wan M, Simonin EM, Johnson MM, Zhang X, Lin X, Gao P, et al. Exposomics: a review of methodologies, applications, and future directions in molecular medicine. *EMBO Mol Med*. 2025;17(4):599–608. <https://doi.org/10.1038/s44321-025-00191-w>.
58. Tobias ES, Avram E, Calapod P, Cordier C, den Dunnen JT, Ding C, et al. The role of the European Society of Human Genetics in delivering genomic education. *Front Genet*. 2021;12:693952. <https://doi.org/10.3389/fgenet.2021.693952>.
59. Hajek C, Hutchinson AM, Galbraith LN, Green RC, Murray MF, Petry N, et al. Improved provider preparedness through an 8-part genetics and genomic education program. *Genet Med*. 2022;24(1):214–24. <https://doi.org/10.1016/j.gim.2021.08.008>.

60. Alfaro TM, Wijsenbeek MS, Powell P, Stolz D, Hurst JR, Kreuter M, et al. Educational aspects of rare and orphan lung diseases. *Respir Res.* 2021;22(1):92. <https://doi.org/10.1186/s12931-021-01676-1>.
61. Gurwitz KT, Singh Gaur P, Bellis LJ, Larcombe L, Alloza E, Balint BL, et al. A framework to assess the quality and impact of bioinformatics training across ELIXIR. *PLoS Comput Biol.* 2020;16(7):e1007976. <https://doi.org/10.1371/journal.pcbi.1007976>.
62. Tumiene B, Peters H, Melegh B, Peterlin B, Utkus A, Fatkulina N, et al. Rare disease education in Europe and beyond: time to act. *Orphanet J Rare Dis.* 2022;17(1):441. <https://doi.org/10.1186/s13023-022-02527-y>.
63. Reinhard C, Bachoud-Lévi AC, Bäumer T, Bertini E, Brunelle A, Buizer AI, et al. The European Reference Network for Rare Neurological Diseases. *Front Neurol.* 2021;11:616569. <https://doi.org/10.3389/fneur.2020.616569>.
64. Groft SC, Gopal-Srivastava R, Dellon ES, Gupta SK. How to advance research, education, and training in the study of rare diseases. *Gastroenterology.* 2019;157(4):917–21. <https://doi.org/10.1053/j.gastro.2019.08.010>.
65. D'Angelo CS, Hermes A, McMaster CR, Pritchep E, Richer É, van der Westhuizen FH, et al. Barriers and Considerations for Diagnosing Rare Diseases in Indigenous Populations. *Front Pediatr.* 2020;14(8):579924. <https://doi.org/10.3389/fped.2020.579924>.
66. Ming Kei Chung, John S House, Farida S Akhtari, Konstantinos C Makris, Michael A Langston, Khandaker Talat Islam, Philip Holmes, Marc Chadeau-Hyam, Alex I Smirnov, Xiuxia Du, Anne E Thessen, Yuxia Cui, Kai Zhang, Arjun K Manrai, Alison Motsinger-Reif, Chirag J Patel, Members of the Exposomics Consortium, Decoding the exposome: data science methodologies and implications in exposome-wide association studies (ExWASs), *Exposome*, 2024. <https://doi.org/10.1093/exposome/osa001>
67. Patel CJ, Bhattacharya J, Butte AJ. An Environment-Wide Association Study (EWAS) on type 2 diabetes mellitus. *PLoS ONE.* 2010;5(5):e10746. <https://doi.org/10.1371/journal.pone.0010746>.
68. Rare diseases: a global health priority for equity and inclusion. World Health Organization. Executive Board 156th session. 4 February 2025. Available at https://apps.who.int/gb/ebwha/pdf_files/EB156/B156_CONF2-en.pdf
69. Kernohan KD, Boycott KM. The expanding diagnostic toolbox for rare genetic diseases. *Nat Rev Genet.* 2024;25(6):401–15. <https://doi.org/10.1038/s41576-023-00683-w>.
70. Gudmundsson S, Singer-Berk M, Watts NA, Phu W, Goodrich JK, Solomonson M, et al. Variant interpretation using population databases: lessons from gnomAD. *Hum Mutat.* 2022;43(8):1012–30. <https://doi.org/10.1002/humu.24309>.
71. Skanharajah N, Baichoo S, Boughtwood TF, Casas-Silva E, Chandrasekharan S, Dave SM, et al. Equity, diversity, and inclusion at the Global Alliance for Genomics and Health. *Cell Genom.* 2023;3(10):100386. <https://doi.org/10.1016/j.xgen.2023.100386>.
72. Weile J, Roth FP. Multiplexed assays of variant effects contribute to a growing genotype-phenotype atlas. *Hum Genet.* 2018;137(9):665–78. <https://doi.org/10.1007/s00439-018-1916-x>.
73. Varadi M, Bertoni D, Magana P, Paramval U, Pidruchna I, Radhakrishnan M, et al. AlphaFold protein structure database in 2024: providing structure coverage for over 214 million protein sequences. *Nucleic Acids Res.* 2024;52(D1):5–D375. <https://doi.org/10.1093/nar/gkad1011>.
74. Kane NJ, Cohen ASA, Berrios C, Jones B, Pastinen T, Hoffman MA. Committing to genomic answers for all kids: evaluating inequity in genomic research enrollment. *Genet Med.* 2023;25(9):100895. <https://doi.org/10.1016/j.gim.2023.100895>.
75. Silcocks M, Farlow A, Hermes A, Tsambos G, Patel HR, Huebner S, et al. Indigenous Australian genomes show deep structure and rich novel variation. *Nature.* 2023;624(7992):593–601. <https://doi.org/10.1038/s41586-023-06831-w>.
76. Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genomic mutational constraint map using variation in 76,156 human genomes. *Nature.* 2024;625(7993):92–100. <https://doi.org/10.1038/s41586-023-06045-0>.
77. Mulder N, Abimiku A, Adebamowo SN, de Vries J, Matimba A, Olowoyo P, et al. H3Africa: current perspectives. *Pharmacogenomics Pers Med.* 2018;11:10–66. <https://doi.org/10.2147/PGPM.S141546>.
78. Wilson LA, Macken WL, Perry LD, Record CJ, Schon KR, Frezatti RSS, et al. Neuromuscular disease genetics in under-represented populations: increasing data diversity. *Brain.* 2023;146(12):1–5109. <https://doi.org/10.1093/brain/awa254>.
79. Taruscio D, Baynam G, Cederroth H, Groft SC, Klee EW, Kosaki K, et al. The Undiagnosed Diseases Network International: Five years and more! *Mol Genet Metab.* 2020;129(4):243–54. <https://doi.org/10.1016/j.ymgme.2020.01.004>.
80. Roberts MC, Fohner AE, Landry L, Olstad DL, Smit AK, Turbitt E, et al. Advancing precision public health using human genomics: examples from the field and future research opportunities. *Genome Med.* 2021;13(1):97. <https://doi.org/10.1186/s13073-021-00911-0>.
81. Deguen S, Amuzu M, Simoncic V, Kihal-Talantikite W. Exposome and social vulnerability: an overview of the literature review. *Int J Environ Res Public Health.* 2022;19(6):3534. <https://doi.org/10.3390/ijerph19063534>.
82. Karlsson O. Chemical safety and the exposome. *Emerg Contam.* 2023;9(2):100225. <https://doi.org/10.1016/j.jemcon.2023.100225>.
83. Pronk A, Loh M, Kuijpers E, Albin M, Selander J, Godderis L, et al. Applying the exposome concept to working life health: the EU EPHOR project. *Environ Epidemiol.* 2022;6(2):e185. <https://doi.org/10.1097/EE9.0000000000000185>.
84. McKinney WS, Williford DN, Abbeduto L, Schmitt LM. The impact of social-environmental factors on IQ in syndromic intellectual developmental disabilities. *J Clin Transl Sci.* 2024;8(1):e59. <https://doi.org/10.1017/cts.2024.510>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.